Cadonilimab plus CapeOX chemotherapy

Phase 2Small molecule

NNanfang Hospital, Southern Medical University

Cadonilimab plus CapeOX chemotherapy is one of 51 small molecule programs targeting First-line Treatment. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

First-Line TreatmentNot yet recruiting

First-Line TreatmentPhase 2

Not yet recruiting

Competition

Competitive Landscape

74 competitors in First-Line Treatment

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

4 2

Lexapro

AbbVie

Phase 3

1 3

Tuoyi

SSun Yat-sen University

Phase 3

6 4

Vepesid

AAvyxa

Phase 3

3 5

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

2 6

Adstiladrin

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

2 7

Effexor

WWyeth-Lederle Vaccines

Phase 3

1 8

Wellbutrin

GGlaxo Dba Glaxosmithkline

Phase 3

1 9

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

1 10

Zoloft

VViatris Specialty LLC

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

First-line Treatment1 trial

Cadonilimab Plus CapeOX as First-Line Treatment for Advanced GC/GEJC With High TMEscore

Not yet recruiting·NNanfang Hospital, Southern Medical University·Phase 2·NCT06202716·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cadonilimab plus CapeOX chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cadonilimab plus CapeOX chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cadonilimab plus CapeOX chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nanfang Hospital, Southern Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNanfang Hospital, Southern Medical University

Cadonilimab plus CapeOX chemotherapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

First-line Treatment1 trial

References

Drug Info

Quick Facts

Related News